RenovoRx Triples Cancer Center Adoption of RenovoCath, Appoints Executive Chairman to Drive Commercial Growth
RNXT sits 34% above its 52-week low of $0.701.
Summary
RenovoRx reported substantial commercial momentum for its FDA-cleared RenovoCath device, tripling its active U.S. cancer centers to 12 and its sales pipeline to 33 centers over the past year. The company has seen over 700 successful procedures since clearance, with increasing repeat purchase orders signaling strong physician satisfaction. To further accelerate adoption, Dr. Ramtin Agah, the company's founder and Chief Medical Officer, has been appointed to the additional role of Executive Chairman. This progress indicates growing clinical demand and positions the company for potential revenue expansion throughout 2026, with the strategic leadership change underscoring a strong focus on commercial execution.
At the time of this announcement, RNXT was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.7M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.